Immuneering Corp (IMRX)
1.585
+0.06
(+3.59%)
USD |
NASDAQ |
May 02, 11:31
Immuneering Enterprise Value: -40.30M for May 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 01, 2024 | -40.30M |
| April 30, 2024 | -43.56M |
| April 29, 2024 | -41.78M |
| April 26, 2024 | -42.08M |
| April 25, 2024 | -43.26M |
| April 24, 2024 | -41.19M |
| April 23, 2024 | -37.33M |
| April 22, 2024 | -34.66M |
| April 19, 2024 | -32.29M |
| April 18, 2024 | -33.18M |
| April 17, 2024 | -31.20M |
| April 16, 2024 | -31.78M |
| April 15, 2024 | -29.59M |
| April 12, 2024 | -24.17M |
| April 11, 2024 | -24.76M |
| April 10, 2024 | -26.81M |
| April 09, 2024 | -21.54M |
| April 08, 2024 | -23.59M |
| April 05, 2024 | -21.54M |
| April 04, 2024 | -16.85M |
| April 03, 2024 | -15.39M |
| April 02, 2024 | -12.46M |
| April 01, 2024 | -5.137M |
| March 28, 2024 | -1.037M |
| March 27, 2024 | -14.51M |
| Date | Value |
|---|---|
| March 26, 2024 | -15.68M |
| March 25, 2024 | -11.58M |
| March 22, 2024 | -10.99M |
| March 21, 2024 | -5.722M |
| March 20, 2024 | -4.258M |
| March 19, 2024 | -10.41M |
| March 18, 2024 | -10.70M |
| March 15, 2024 | -29.73M |
| March 14, 2024 | -0.7441M |
| March 13, 2024 | 86.52M |
| March 12, 2024 | 85.79M |
| March 11, 2024 | 88.13M |
| March 08, 2024 | 106.43M |
| March 07, 2024 | 109.95M |
| March 06, 2024 | 101.75M |
| March 05, 2024 | 95.89M |
| March 04, 2024 | 94.43M |
| March 01, 2024 | 94.43M |
| February 29, 2024 | 95.89M |
| February 28, 2024 | 100.28M |
| February 27, 2024 | 102.63M |
| February 26, 2024 | 101.45M |
| February 23, 2024 | 103.50M |
| February 22, 2024 | 102.26M |
| February 21, 2024 | 106.94M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-43.56M
Minimum
Apr 30 2024
801.56M
Maximum
Sep 27 2021
162.31M
Average
107.64M
Median
Nov 21 2023
Enterprise Value Benchmarks
| Geron Corp | 1.973B |
| SELLAS Life Sciences Group Inc | 68.93M |
| Elicio Therapeutics Inc | 77.56M |
| Vistagen Therapeutics Inc | 0.9997M |
| ADMA Biologics Inc | 1.601B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -15.08M |
| Total Expenses (Quarterly) | 16.30M |
| EPS Diluted (Quarterly) | -0.52 |
| Earnings Yield | -119.2% |
| Normalized Earnings Yield | -121.14 |